GM-CSF regulates a PU.1-dependent transcriptional program determining the pulmonary response to LPS.

Alveolar macrophages (AMs) normally respond to lipopolysaccharide (LPS) by activating Toll-like receptor (TLR)-4 signaling, a mechanism critical to lung host defense against gram-negative bacteria such as Pseudomonas aeruginosa. Because granulocyte macrophage colony-stimulating factor (GM-CSF)-deficient (GM(-/-)) mice are hyporesponsive to LPS, we evaluated the role of GM-CSF in TLR-4 signaling in AMs. Pulmonary TNF-alpha levels and neutrophil recruitment 4 h after intratracheal administration of Pseudomonas LPS were reduced in GM(-/-) compared with wild-type (GM(+/+)) mice. Secretion of TNF-alpha by AMs exposed to LPS ex vivo was also reduced in GM(-/-) mice and restored in mice expressing GM-CSF specifically in the lungs (SPC-GM(+/+)/GM(-/-) mice). LPS-dependent NF-kappaB promoter activity, TNF-alpha secretion, and neutrophil chemokine release were reduced in AM cell lines derived from GM(-/-) mice (mAM) compared with GM(+/+) (MH-S). Retroviral expression of PU.1 in mAM cells, which normally lack PU.1, rescued all of these AM defects. To determine whether GM-CSF, via PU.1, regulated expression of TLR-4 pathway components, mRNA and protein levels for key components were evaluated in MH-S cells (GM(+/+), PU.1(Positive)), mAM cells (GM(-/-), PU.1(Negative)), and mAMPU.1+ cells (GM(-/-), PU.1(Positive)). Cluster of differentiation antigen-14, radioprotective 105, IL-1 receptor-associated kinase (IRAK)-M mRNA, and protein were dependent upon GM-CSF and restored by expression of PU.1. In contrast, expression of other TLR-4 pathway components (myeloid differentiation-2, TLR-4, IRAK-1, IRAK-2, Toll/IL-1 receptor domain containing adapter protein/MyD88 adaptor-like, myeloid differentiation primary-response protein 88, IRAK-4, TNF receptor-associated factor-6, NF-kappaB, inhibitor of NF-kappaB kinase) were not GM-CSF or PU.1-dependent. These results show that GM-CSF, via PU.1, enables AM responses to P. aeruginosa LPS by regulating expression of a specific subset of components of the TLR-4 signaling pathway.

[1]  B. Trapnell,et al.  Disruption of granulocyte macrophage‐colony stimulating factor production in the lungs severely affects the ability of mice to control Mycobacterium tuberculosis infection , 2005, Journal of leukocyte biology.

[2]  A. Tarakhovsky,et al.  Negative regulation of Toll-like receptor 4 signaling by the Toll-like receptor homolog RP105 , 2005, Nature Immunology.

[3]  Shizuo Akira,et al.  Toll-like receptor signalling , 2004, Nature Reviews Immunology.

[4]  J. Hamilton,et al.  Innate immune responses to LPS in mouse lung are suppressed and reversed by neutralization of GM-CSF via repression of TLR-4. , 2004, American journal of physiology. Lung cellular and molecular physiology.

[5]  Y. Eishi,et al.  High-affinity autoantibodies specifically eliminate granulocyte-macrophage colony-stimulating factor activity in the lungs of patients with idiopathic pulmonary alveolar proteinosis. , 2003, Blood.

[6]  B. Trapnell,et al.  PU.1 regulation of human alveolar macrophage differentiation requires granulocyte-macrophage colony-stimulating factor. , 2003, American journal of physiology. Lung cellular and molecular physiology.

[7]  J. Whitsett,et al.  Endocytic Internalization of Adenovirus, Nonspecific Phagocytosis, and Cytoskeletal Organization Are Coordinately Regulated in Alveolar Macrophages by GM-CSF and PU.11 , 2002, The Journal of Immunology.

[8]  J. Whitsett,et al.  GM-CSF, via PU.1, regulates alveolar macrophage FcγR-mediated phagocytosis and the IL-18/IFN-γ–mediated molecular connection between innate and adaptive immunity in the lung , 2002 .

[9]  A. Prince,et al.  Bacterial stimulation of epithelial G-CSF and GM-CSF expression promotes PMN survival in CF airways. , 2002, American journal of respiratory cell and molecular biology.

[10]  Charles A. Janeway,et al.  IRAK-M Is a Negative Regulator of Toll-like Receptor Signaling , 2002, Cell.

[11]  J. Seymour,et al.  Pulmonary alveolar proteinosis: progress in the first 44 years. , 2002, American journal of respiratory and critical care medicine.

[12]  J. Whitsett,et al.  Gm-CSF regulates pulmonary surfactant homeostasis and alveolar macrophage-mediated innate host defense. , 2002, Annual review of physiology.

[13]  J. Whitsett,et al.  GM-CSF, via PU.1, regulates alveolar macrophage Fcgamma R-mediated phagocytosis and the IL-18/IFN-gamma -mediated molecular connection between innate and adaptive immunity in the lung. , 2002, Blood.

[14]  Alan Aderem,et al.  Edinburgh Research Explorer Macrophages exposed continuously to lipopolysaccharide and other agonists that act via toll-like receptors exhibit a sustained and additive activation state , 2001 .

[15]  J. Whitsett,et al.  GM-CSF regulates alveolar macrophage differentiation and innate immunity in the lung through PU.1. , 2001, Immunity.

[16]  S. Randell,et al.  CD14-dependent Lipopolysaccharide-induced β-Defensin-2 Expression in Human Tracheobronchial Epithelium* , 2000, The Journal of Biological Chemistry.

[17]  H. Singh,et al.  Regulation of B lymphocyte and macrophage development by graded expression of PU.1. , 2000, Science.

[18]  J. Whitsett,et al.  Granulocyte-Macrophage Colony-Stimulating Factor in the Innate Immune Response to Pneumocystis carinii Pneumonia in Mice1 , 2000, The Journal of Immunology.

[19]  J. Whitsett,et al.  Granulocyte-Macrophage Colony-Stimulating Factor in the Innate Immune Response toPneumocystis carinii Pneumonia in Mice , 2000 .

[20]  W. Lu,et al.  Aerosolized GM-CSF ameliorates pulmonary alveolar proteinosis in GM-CSF-deficient mice. , 1999, American journal of physiology. Lung cellular and molecular physiology.

[21]  J. Whitsett,et al.  GM-CSF-deficient mice are susceptible to pulmonary group B streptococcal infection. , 1999, The Journal of clinical investigation.

[22]  P. Ricciardi-Castagnoli,et al.  Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. , 1998, Science.

[23]  B. Trapnell,et al.  Nonspecific inflammation inhibits adenovirus-mediated pulmonary gene transfer and expression independent of specific acquired immune responses. , 1998, Human gene therapy.

[24]  C. Janeway,et al.  MyD88 is an adaptor protein in the hToll/IL-1 receptor family signaling pathways. , 1998, Molecular cell.

[25]  K. Irie,et al.  The oncoprotein Evi-1 represses TGF-beta signalling by inhibiting Smad3. , 1998, Nature.

[26]  C. Quilici,et al.  Mice lacking both granulocyte colony-stimulating factor (CSF) and granulocyte-macrophage CSF have impaired reproductive capacity, perturbed neonatal granulopoiesis, lung disease, amyloidosis, and reduced long-term survival. , 1997, Blood.

[27]  G. Dranoff,et al.  GM-CSF enhances lung growth and causes alveolar type II epithelial cell hyperplasia in transgenic mice. , 1997, American journal of physiology. Lung cellular and molecular physiology.

[28]  M. Marino,et al.  Increased tolerance to endotoxin by granulocyte-macrophage colony-stimulating factor-deficient mice. , 1997, Journal of immunology.

[29]  G. Dranoff,et al.  Surfactant metabolism in transgenic mice after granulocyte macrophage-colony stimulating factor ablation. , 1996, The American journal of physiology.

[30]  G. Dranoff,et al.  Pulmonary epithelial cell expression of GM-CSF corrects the alveolar proteinosis in GM-CSF-deficient mice. , 1996, The Journal of clinical investigation.

[31]  J. Sheridan,et al.  Requirement of MIP-1 alpha for an inflammatory response to viral infection. , 1995, Science.

[32]  P. Ward,et al.  Role of macrophage inflammatory protein-1 alpha (MIP-1 alpha) in acute lung injury in rats. , 1995, Journal of immunology.

[33]  A. Dunn,et al.  Granulocyte/macrophage colony-stimulating factor-deficient mice show no major perturbation of hematopoiesis but develop a characteristic pulmonary pathology. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[34]  G. Dranoff,et al.  Involvement of granulocyte-macrophage colony-stimulating factor in pulmonary homeostasis. , 1994, Science.

[35]  I. Mbawuike,et al.  MH‐S, a Murine Alveolar Macrophage Cell Line: Morphological, Cytochemical, and Functional Characteristics , 1989, Journal of leukocyte biology.

[36]  R. Gonzalez-Rothi,et al.  Pulmonary alveolar proteinosis. Further evaluation of abnormal alveolar macrophages. , 1986, Chest.

[37]  E. Pesanti,et al.  Macrophage function in pulmonary alveolar proteinosis. , 2015, The American review of respiratory disease.

[38]  J. Harris.  Pulmonary alveolar proteinosis: abnormal in vitro function of alveolar macrophages. , 1979, Chest.

[39]  T. N. Finley,et al.  Defective lung macrophages in pulmonary alveolar proteinosis. , 1976, Annals of internal medicine.

[40]  E. Goldstein,et al.  Pulmonary alveolar macrophage. Defender against bacterial infection of the lung. , 1974, The Journal of clinical investigation.

[41]  L. Teppo,et al.  Pulmonary alveolar proteinosis. , 1966, Annales chirurgiae et gynaecologiae Fenniae.